Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex.


Journal

PharmacoEconomics - open
ISSN: 2509-4254
Titre abrégé: Pharmacoecon Open
Pays: Switzerland
ID NLM: 101700780

Informations de publication

Date de publication:
Jan 2022
Historique:
accepted: 27 07 2021
pubmed: 16 9 2021
medline: 16 9 2021
entrez: 15 9 2021
Statut: ppublish

Résumé

Tuberous sclerosis complex (TSC) is a rare multisystem disorder often associated with treatment-resistant epilepsy. Cost-effectiveness analysis for new antiseizure medications typically requires health state utilities (HSUs) that reflect the burden of a given condition. This study aimed to estimate HSUs, with a focus on valuing the impact of seizure type and seizure frequency on health-related quality of life (HRQL) for patients with TSC and their caregivers. A targeted literature review and qualitative research with healthcare professionals and caregivers informed the development of health state vignettes describing the experience of living with TSC or caring for a child with TSC. Vignettes were evaluated in interviews with the UK general population using the time trade-off (TTO) method. Sixteen vignettes were developed describing patient HRQL (n = 8) and caregiver HRQL (n = 8). Two hundred interviews were conducted via online video calls due to COVID-19 pandemic restrictions. Two hundred participants evaluated the patient (n = 100) and caregiver (n = 100) health state vignettes. Estimated utility scores varied consistently according to seizure type and seizure frequency. Patient TTO utility scores ranged between -0.234 (highest seizure frequency and multiple seizure types) and 0.725 (seizure-free state). Caregiver TTO utility scores ranged from 0.221 to 0.905. Findings highlight the substantial burden of living with TSC and caring for a child with TSC. Patient and caregiver burden was greater for generalised versus focal seizures. The burden was greatest for a combination of both seizure types and worsened with increasing seizure frequency.

Sections du résumé

BACKGROUND BACKGROUND
Tuberous sclerosis complex (TSC) is a rare multisystem disorder often associated with treatment-resistant epilepsy. Cost-effectiveness analysis for new antiseizure medications typically requires health state utilities (HSUs) that reflect the burden of a given condition.
OBJECTIVE OBJECTIVE
This study aimed to estimate HSUs, with a focus on valuing the impact of seizure type and seizure frequency on health-related quality of life (HRQL) for patients with TSC and their caregivers.
METHODS METHODS
A targeted literature review and qualitative research with healthcare professionals and caregivers informed the development of health state vignettes describing the experience of living with TSC or caring for a child with TSC. Vignettes were evaluated in interviews with the UK general population using the time trade-off (TTO) method.
RESULTS RESULTS
Sixteen vignettes were developed describing patient HRQL (n = 8) and caregiver HRQL (n = 8). Two hundred interviews were conducted via online video calls due to COVID-19 pandemic restrictions. Two hundred participants evaluated the patient (n = 100) and caregiver (n = 100) health state vignettes. Estimated utility scores varied consistently according to seizure type and seizure frequency. Patient TTO utility scores ranged between -0.234 (highest seizure frequency and multiple seizure types) and 0.725 (seizure-free state). Caregiver TTO utility scores ranged from 0.221 to 0.905.
CONCLUSIONS CONCLUSIONS
Findings highlight the substantial burden of living with TSC and caring for a child with TSC. Patient and caregiver burden was greater for generalised versus focal seizures. The burden was greatest for a combination of both seizure types and worsened with increasing seizure frequency.

Identifiants

pubmed: 34524653
doi: 10.1007/s41669-021-00296-1
pii: 10.1007/s41669-021-00296-1
pmc: PMC8441242
doi:

Types de publication

Journal Article

Langues

eng

Pagination

105-121

Informations de copyright

© 2021. The Author(s).

Références

Orphanet J Rare Dis. 2017 Jan 5;12(1):2
pubmed: 28057044
Epilepsy Behav. 2018 Jun;83:13-21
pubmed: 29631156
Cold Spring Harb Perspect Med. 2015 Jun 01;5(6):
pubmed: 26033084
Epilepsia. 2010 Jul;51(7):1236-41
pubmed: 20041940
Dev Med Child Neurol. 2020 Mar;62(3):322-329
pubmed: 31538337
Epilepsy Behav. 2019 Jul;96:23-27
pubmed: 31077938
J Intellect Disabil Res. 2019 Aug;63(8):947-956
pubmed: 30775832
J Child Neurol. 2013 Apr;28(4):461-9
pubmed: 22772159
J Neurol. 2017 Jun;264(6):1146-1154
pubmed: 28516327
Int Sch Res Notices. 2017 Nov 15;2017:8404378
pubmed: 29270462
Qual Life Res. 2019 May;28(5):1191-1199
pubmed: 30767088
J Neurol Sci. 2018 Aug 15;391:104-108
pubmed: 30103955
Epilepsia Open. 2018 Dec 21;4(1):73-84
pubmed: 30868117
Orphanet J Rare Dis. 2020 Jan 21;15(1):23
pubmed: 31964424
Epilepsia Open. 2019 Oct 27;4(4):581-592
pubmed: 31819914
J Child Neurol. 2015 Apr;30(5):563-9
pubmed: 24667738
J Med Econ. 2018 Oct;21(10):953-959
pubmed: 29890870
Epilepsy Behav. 2011 Mar;20(3):561-5
pubmed: 21288778
Front Neurol. 2019 Oct 25;10:1144
pubmed: 31708865
Eur J Paediatr Neurol. 2012 Nov;16(6):582-6
pubmed: 22695035
Seizure. 2009 Oct;18(8):554-8
pubmed: 19592271
Epilepsy Behav. 2019 Mar;92:213-220
pubmed: 30690322
Pediatr Neurol. 2013 Oct;49(4):243-54
pubmed: 24053982
J Health Econ. 1986 Mar;5(1):1-30
pubmed: 10311607
Qual Life Res. 2017 Mar;26(3):749-759
pubmed: 28004320
Epilepsy Behav. 2008 Oct;13(3):505-10
pubmed: 18602868
Arch Dis Child. 2019 Oct;104(10):972-978
pubmed: 31122923
Seizure. 2010 Jan;19(1):23-30
pubmed: 19948417
Epilepsia. 2016 Sep;57(9):1443-9
pubmed: 27417921
Eur J Paediatr Neurol. 2019 Nov;23(6):801-807
pubmed: 31543331
BMJ Open. 2013 Dec 06;3(12):e003707
pubmed: 24319280
J Child Neurol. 2015 Oct;30(12):1574-81
pubmed: 25838447
Pediatr Neurol. 2015 Apr;52(4):435-41
pubmed: 25771998
J Med Econ. 2016 Dec;19(12):1116-1126
pubmed: 27310569
Patient. 2021 Sep;14(5):459-469
pubmed: 33345290
Pediatr Dermatol. 2016 Sep;33(5):518-25
pubmed: 27436143
Am J Med Genet C Semin Med Genet. 2018 Sep;178(3):309-320
pubmed: 30117265
Eur J Health Econ. 2018 Jul;19(6):861-870
pubmed: 28871490
Leuk Lymphoma. 2015 May;56(5):1320-6
pubmed: 25213185
Patient Prefer Adherence. 2015 Nov 03;9:1561-72
pubmed: 26604709
Value Health. 2014 Jun;17(4):445-53
pubmed: 24969006
Epilepsia. 2010 Nov;51(11):2316-21
pubmed: 20633038
Pediatr Neurol. 2010 Jul;43(1):29-34
pubmed: 20682200
Asia Pac J Clin Oncol. 2017 Oct;13(5):e195-e203
pubmed: 26990789
Brain. 2020 Feb 1;143(2):570-581
pubmed: 31953931
N Engl J Med. 2010 Nov 4;363(19):1801-11
pubmed: 21047224
J Med Econ. 2016 Nov;19(11):1087-1098
pubmed: 27267148

Auteurs

Siu Hing Lo (SH)

Acaster Lloyd Consulting Ltd, 16 Upper Woburn Place, Bloomsbury, London, WC1H 0BS, UK. siuhing.lo@acasterlloyd.com.

Jade Marshall (J)

GW Pharma Ltd, 1 Cavendish Place, Marylebone, London, W1G 0QF, UK.

Hanna Skrobanski (H)

Acaster Lloyd Consulting Ltd, 16 Upper Woburn Place, Bloomsbury, London, WC1H 0BS, UK.

Andrew Lloyd (A)

Acaster Lloyd Consulting Ltd, 16 Upper Woburn Place, Bloomsbury, London, WC1H 0BS, UK.

Classifications MeSH